A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice.
Clinical diagnosis
Early-onset retinal dystrophy
Inherited retinal diseases
Leber congenital amaurosis
Molecular diagnosis
Multidisciplinary
Retinitis pigmentosa
Visual function
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
31 07 2023
31 07 2023
Historique:
received:
10
10
2022
accepted:
05
07
2023
medline:
2
8
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
Non-syndromic inherited retinal dystrophies (IRDs) such as retinitis pigmentosa or Leber congenital amaurosis generally manifest between early childhood and late adolescence, imposing profound long-term impacts as a result of vision impairment or blindness. IRDs are highly heterogeneous, with often overlapping symptoms among different IRDs, and achieving a definite diagnosis is challenging. This narrative review provides a clinical overview of the non-syndromic generalized photoreceptor dystrophies, particularly retinitis pigmentosa and Leber congenital amaurosis. The clinical investigations and genetic testing needed to establish a diagnosis are outlined, and current management approaches are discussed, focusing on the importance of the involvement of an interdisciplinary team from diagnosis and initial care to long-term follow-up and support. The effective management of IRDs requires a multidisciplinary, and ideally interdisciplinary, team of experts knowledgeable about IRDs, with experienced professionals from fields as diverse as ophthalmology, neuropsychiatry, psychology, neurology, genetics, orthoptics, developmental therapy, typhlology, occupational therapy, otolaryngology, and orientation and mobility specialties. Accurate clinical diagnosis encompasses a range of objective and subjective assessments as a prerequisite for the genetic testing essential in establishing an accurate diagnosis necessary for the effective management of IRDs, particularly in the era of gene therapies. Improvements in genome sequencing techniques, such as next-generation sequencing, have greatly facilitated the complex process of determining IRD-causing gene variants and establishing a molecular diagnosis. Genetic counseling is essential to help the individual and their family understand the condition, the potential risk for offspring, and the implications of a diagnosis on visual prognosis and treatment options. Psychological support for patients and caregivers is important at all stages of diagnosis, care, and rehabilitation and is an essential part of the multidisciplinary approach to managing IRDs. Effective communication throughout is essential, and the patient and caregivers' needs and expectations must be acknowledged and discussed. As IRDs can present at an early age, clinicians need to be aware of the clinical signs suggesting visual impairment and follow up with multidisciplinary support for timely diagnoses to facilitate appropriate therapeutic or rehabilitation intervention to minimize vision loss.
Sections du résumé
BACKGROUND
Non-syndromic inherited retinal dystrophies (IRDs) such as retinitis pigmentosa or Leber congenital amaurosis generally manifest between early childhood and late adolescence, imposing profound long-term impacts as a result of vision impairment or blindness. IRDs are highly heterogeneous, with often overlapping symptoms among different IRDs, and achieving a definite diagnosis is challenging. This narrative review provides a clinical overview of the non-syndromic generalized photoreceptor dystrophies, particularly retinitis pigmentosa and Leber congenital amaurosis. The clinical investigations and genetic testing needed to establish a diagnosis are outlined, and current management approaches are discussed, focusing on the importance of the involvement of an interdisciplinary team from diagnosis and initial care to long-term follow-up and support.
RESULTS
The effective management of IRDs requires a multidisciplinary, and ideally interdisciplinary, team of experts knowledgeable about IRDs, with experienced professionals from fields as diverse as ophthalmology, neuropsychiatry, psychology, neurology, genetics, orthoptics, developmental therapy, typhlology, occupational therapy, otolaryngology, and orientation and mobility specialties. Accurate clinical diagnosis encompasses a range of objective and subjective assessments as a prerequisite for the genetic testing essential in establishing an accurate diagnosis necessary for the effective management of IRDs, particularly in the era of gene therapies. Improvements in genome sequencing techniques, such as next-generation sequencing, have greatly facilitated the complex process of determining IRD-causing gene variants and establishing a molecular diagnosis. Genetic counseling is essential to help the individual and their family understand the condition, the potential risk for offspring, and the implications of a diagnosis on visual prognosis and treatment options. Psychological support for patients and caregivers is important at all stages of diagnosis, care, and rehabilitation and is an essential part of the multidisciplinary approach to managing IRDs. Effective communication throughout is essential, and the patient and caregivers' needs and expectations must be acknowledged and discussed.
CONCLUSION
As IRDs can present at an early age, clinicians need to be aware of the clinical signs suggesting visual impairment and follow up with multidisciplinary support for timely diagnoses to facilitate appropriate therapeutic or rehabilitation intervention to minimize vision loss.
Identifiants
pubmed: 37525225
doi: 10.1186/s13023-023-02798-z
pii: 10.1186/s13023-023-02798-z
pmc: PMC10388566
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
223Informations de copyright
© 2023. The Author(s).
Références
Mol Vis. 2007 Apr 05;13:588-93
pubmed: 17438524
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1601-1609
pubmed: 31049658
Br J Ophthalmol. 2017 Sep;101(9):1147-1154
pubmed: 28689169
Invest Ophthalmol Vis Sci. 1995 Mar;36(3):718-29
pubmed: 7890502
Am J Ophthalmol. 1985 Mar 15;99(3):240-51
pubmed: 3976802
Lancet. 2006 Nov 18;368(9549):1795-809
pubmed: 17113430
Cell. 2018 Mar 22;173(1):5
pubmed: 29570997
Am J Ophthalmol. 2014 Nov;158(5):1093-8
pubmed: 25062603
Mol Diagn Ther. 2019 Feb;23(1):113-120
pubmed: 30569401
Clin Exp Ophthalmol. 2021 Jul;49(5):498-515
pubmed: 34013643
Retina. 2010 Nov-Dec;30(10):1704-13
pubmed: 20829743
Prog Retin Eye Res. 1998 Apr;17(2):175-205
pubmed: 9695792
Genes (Basel). 2019 Dec 24;11(1):
pubmed: 31878136
Ophthalmology. 2019 Oct;126(10):1466-1468
pubmed: 31028769
Genome Biol. 2017 Nov 28;18(1):225
pubmed: 29179779
J Pers Soc Psychol. 2004 Jul;87(1):133-45
pubmed: 15250798
Acta Ophthalmol. 2010 Mar;88(2):163-73
pubmed: 20039847
Prog Retin Eye Res. 2011 Jul;30(4):258-74
pubmed: 21477661
Int J Mol Sci. 2021 Jul 05;22(13):
pubmed: 34281261
Mol Vis. 2017 Jul 20;23:470-481
pubmed: 28761320
Lancet Neurol. 2013 Sep;12(9):894-905
pubmed: 23870701
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33926102
Mol Vis. 2021 Feb 05;27:78-94
pubmed: 33688152
Retina. 2017 Mar;37(3):417-423
pubmed: 27753762
Hum Mutat. 2010 Oct;31(10):E1709-66
pubmed: 20683928
Int J Retina Vitreous. 2017 Jan 09;3:1
pubmed: 28078103
Genet Med. 2020 Jul;22(7):1235-1246
pubmed: 32307445
Exp Eye Res. 2019 Dec;189:107834
pubmed: 31639339
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3642-55
pubmed: 26047050
Sci Rep. 2021 Jan 15;11(1):1526
pubmed: 33452396
Br J Ophthalmol. 2013 Aug;97(8):1057-61
pubmed: 23740962
Int J Mol Sci. 2021 May 26;22(11):
pubmed: 34073611
Ophthalmology. 2017 Sep;124(9):1314-1331
pubmed: 28559085
Orphanet J Rare Dis. 2021 Jun 4;16(1):257
pubmed: 34088339
Am J Ophthalmol. 2019 Mar;199:58-70
pubmed: 30268864
J Patient Rep Outcomes. 2021 Jan 13;5(1):7
pubmed: 33439361
Sci Rep. 2018 Sep 3;8(1):13130
pubmed: 30177829
Hum Mol Genet. 2002 May 15;11(10):1219-27
pubmed: 12015282
N Engl J Med. 2015 Jun 4;372(23):2235-42
pubmed: 26014595
Surv Ophthalmol. 2020 May - Jun;65(3):294-311
pubmed: 31783046
Retina. 2014 May;34(5):981-8
pubmed: 24756036
Prog Retin Eye Res. 2018 Sep;66:157-186
pubmed: 29597005
J Clin Invest. 2010 Sep;120(9):3042-53
pubmed: 20811160
Qual Life Res. 2016 Oct;25(10):2633-2643
pubmed: 27076189
Genet Med. 2019 Jun;21(6):1267-1270
pubmed: 31015575
Genes (Basel). 2020 Sep 24;11(10):
pubmed: 32987769
Br J Ophthalmol. 2017 Jan;101(1):31-37
pubmed: 27913439
Hum Mol Genet. 2017 Aug 1;26(R1):R2-R11
pubmed: 28510639
Ophthalmology. 2020 Oct;127(10):1384-1394
pubmed: 32423767
Genet Med. 2016 Aug;18(8):755-62
pubmed: 26741411
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Ophthalmologica. 2019;242(4):195-207
pubmed: 31416074
Eur J Ophthalmol. 2018 Jan;28(1):52-57
pubmed: 28604982
Can J Ophthalmol. 2006 Jun;41(3):289-312
pubmed: 16767184
Int Ophthalmol. 2021 Dec;41(12):3949-3959
pubmed: 34304340
Prog Retin Eye Res. 2021 May;82:100898
pubmed: 32860923
Prog Retin Eye Res. 2021 Mar;81:100893
pubmed: 32758681
Eye (Lond). 2023 Jan;37(1):42-47
pubmed: 34974539
Retina. 2022 Feb 1;42(2):388-395
pubmed: 34510128
Prog Retin Eye Res. 2008 Jul;27(4):391-419
pubmed: 18632300
Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3597-3604
pubmed: 34287692
Hum Mutat. 2012 Jun;33(6):963-72
pubmed: 22334370
Eur J Hum Genet. 2016 Jul;24(7):1071-9
pubmed: 26626312
Clin Exp Ophthalmol. 2019 Jul;47(5):605-613
pubmed: 30552737
Front Neurosci. 2020 Jul 24;14:768
pubmed: 32792904
J Med Genet. 2019 Aug;56(8):536-542
pubmed: 30910914
JAMA Ophthalmol. 2019 Dec 1;137(12):1381-1388
pubmed: 31580392
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):9-22
pubmed: 30324420
J Community Genet. 2019 Jul;10(3):425-434
pubmed: 30680631
Coll Antropol. 2009 Mar;33(1):303-10
pubmed: 19408642
Am J Ophthalmol. 2008 Apr;145(4):687-94
pubmed: 18242574
Ophthalmic Res. 2016;56(3):111-22
pubmed: 27352292
J Child Neurol. 2016 Apr;31(5):652-62
pubmed: 26275973
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Transl Vis Sci Technol. 2021 Aug 12;10(10):11
pubmed: 34554209
Transl Sci Rare Dis. 2019 Jul 04;4(1-2):97-115
pubmed: 31763178
Genes (Basel). 2021 Aug 19;12(8):
pubmed: 34440435
Ophthalmology. 2013 Sep;120(9):1827-34
pubmed: 23631947
J Med Genet. 2019 May;56(5):325-331
pubmed: 30573563
JAMA Ophthalmol. 2020 Oct 1;138(10):1035-1042
pubmed: 32815999